国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2014年
2期
114-116
,共3页
陈晓%周晓春%金艺璇%吴卫明%钱玲玲
陳曉%週曉春%金藝璇%吳衛明%錢玲玲
진효%주효춘%금예선%오위명%전령령
2型糖尿病%黄芪%二甲双胍%胰岛素抵抗%胰淀素
2型糖尿病%黃芪%二甲雙胍%胰島素牴抗%胰澱素
2형당뇨병%황기%이갑쌍고%이도소저항%이정소
Type 2 diabetes mellitus%Astragalus%Metformin%Insulin resistance%Amylin
目的 观察黄芪联合二甲双胍对初诊2型糖尿病患者胰岛素抵抗及血浆胰淀素(Amylin)水平的影响.方法 纳入初诊2型糖尿病患者88例,按随机数字表法将患者分为A组(生活方式干预组)30例,B组(二甲双胍治疗组)30例,C组(黄芪联合二甲双胍治疗组)28例.A组给予控制饮食,增加运动,控制血压、血脂等治疗;B组在生活方式干预组基础上加用二甲双胍治疗;C组在B组基础上加用黄芪治疗,疗程均为8周,比较三组治疗前后空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三脂(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HIDL-C)、低密度腊蛋白胆固醇(LDL-C)、空腹血糖(FPG);糖化血红蛋白(HbA1c);空腹胰岛素(F-Ins)、胰岛素抵抗指数(Homa-IR)、β细胞功能指数(Homa-β)及Amylin水平.结果 三组经过治疗后,FPG均明显下降(t值分别为-2.696、-4.029、-3.995,P均＜0.05),且B、C两组的降糖效果优于A组(t值分别为-2.245、-3.493,P均＜0.05);C组F-Ins下降较A组明显(t=-2.305,P＜0.05);B、C两组均能降低Homa-IR(t值分别为-2.599、-3.813,P＜0.05),且C组降低的幅度要优于B组(t=-2.334,P＜0.05);B、C两组均能提高Homa-β(t值分别为2.303、2.384,P均＜0.05)及Amylin水平(t值分别为2.341、3.045,P均＜0.05).结论 黄芪联合二甲双胍可改善初诊2型糖尿病患者的胰岛素抵抗,并提高Homa-β水平.
目的 觀察黃芪聯閤二甲雙胍對初診2型糖尿病患者胰島素牴抗及血漿胰澱素(Amylin)水平的影響.方法 納入初診2型糖尿病患者88例,按隨機數字錶法將患者分為A組(生活方式榦預組)30例,B組(二甲雙胍治療組)30例,C組(黃芪聯閤二甲雙胍治療組)28例.A組給予控製飲食,增加運動,控製血壓、血脂等治療;B組在生活方式榦預組基礎上加用二甲雙胍治療;C組在B組基礎上加用黃芪治療,療程均為8週,比較三組治療前後空腹血糖(FPG)、糖化血紅蛋白(HbA1c)、甘油三脂(TG)、總膽固醇(TC)、高密度脂蛋白膽固醇(HIDL-C)、低密度臘蛋白膽固醇(LDL-C)、空腹血糖(FPG);糖化血紅蛋白(HbA1c);空腹胰島素(F-Ins)、胰島素牴抗指數(Homa-IR)、β細胞功能指數(Homa-β)及Amylin水平.結果 三組經過治療後,FPG均明顯下降(t值分彆為-2.696、-4.029、-3.995,P均＜0.05),且B、C兩組的降糖效果優于A組(t值分彆為-2.245、-3.493,P均＜0.05);C組F-Ins下降較A組明顯(t=-2.305,P＜0.05);B、C兩組均能降低Homa-IR(t值分彆為-2.599、-3.813,P＜0.05),且C組降低的幅度要優于B組(t=-2.334,P＜0.05);B、C兩組均能提高Homa-β(t值分彆為2.303、2.384,P均＜0.05)及Amylin水平(t值分彆為2.341、3.045,P均＜0.05).結論 黃芪聯閤二甲雙胍可改善初診2型糖尿病患者的胰島素牴抗,併提高Homa-β水平.
목적 관찰황기연합이갑쌍고대초진2형당뇨병환자이도소저항급혈장이정소(Amylin)수평적영향.방법 납입초진2형당뇨병환자88례,안수궤수자표법장환자분위A조(생활방식간예조)30례,B조(이갑쌍고치료조)30례,C조(황기연합이갑쌍고치료조)28례.A조급여공제음식,증가운동,공제혈압、혈지등치료;B조재생활방식간예조기출상가용이갑쌍고치료;C조재B조기출상가용황기치료,료정균위8주,비교삼조치료전후공복혈당(FPG)、당화혈홍단백(HbA1c)、감유삼지(TG)、총담고순(TC)、고밀도지단백담고순(HIDL-C)、저밀도석단백담고순(LDL-C)、공복혈당(FPG);당화혈홍단백(HbA1c);공복이도소(F-Ins)、이도소저항지수(Homa-IR)、β세포공능지수(Homa-β)급Amylin수평.결과 삼조경과치료후,FPG균명현하강(t치분별위-2.696、-4.029、-3.995,P균＜0.05),차B、C량조적강당효과우우A조(t치분별위-2.245、-3.493,P균＜0.05);C조F-Ins하강교A조명현(t=-2.305,P＜0.05);B、C량조균능강저Homa-IR(t치분별위-2.599、-3.813,P＜0.05),차C조강저적폭도요우우B조(t=-2.334,P＜0.05);B、C량조균능제고Homa-β(t치분별위2.303、2.384,P균＜0.05)급Amylin수평(t치분별위2.341、3.045,P균＜0.05).결론 황기연합이갑쌍고가개선초진2형당뇨병환자적이도소저항,병제고Homa-β수평.
Objective To understand the effect of astragalus on insulin resistance and plasma amylin levels in newly diagnosed type 2 diabetic patients.Methods 88 patients of newly diagnosed type 2 diabetes were randomly divided into three groups:Group A (lifestyle intervention group) contained 30 patients,Group B (metformin treatment group) also contained 30 Patients,and Group C (astragalus and metformin treatment group) contained 28 Patients.Patients in group A were intervened with the control of diet,blood pressure and lipids level; patients in group B were additionally treated with metformin on the basis of group A; patients in group C were additionally treated with metformin and astragalus on the basis of group A.The course for both treatments were 8 weeks.Various clinical and biochemical parameters were detected before and after the treatment in all three groups and enzyme-linked immunosorbent assay was adopted for the detection of plasma amylin.Results Fasting blood glucose levels were significantly decreased after treataent in the three groups (t=-2.696、-4.029、-3.995,P＜0.05) ; insulin resistance index reduced in group B and group C (t=-2.599、-3.813,P＜0.05),the difference between group C and group B was statistically significant (t=-2.334,P＜0.05) ;treatments of group B and group C could improve the beta cell function index (t=2.303、2.384,P＜0.05),and they also could increase the plasma amylin level (t=2.341、3.045,P＜0.05).Conclusion Astragalus and metformin can improve insulin resistance index and increase plasma amylin levels in newly diagnosed type 2 diabetic patients.
